

Garnet L Anderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/42020/publications.pdf>

Version: 2024-02-01

166
papers

39,742
citations

18465

62
h-index

5820

161
g-index

174
all docs

174
docs citations

174
times ranked

28159
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA - Journal of the American Medical Association, 2002, 288, 321-333.	3.8	14,536
2	Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. JAMA - Journal of the American Medical Association, 2004, 291, 1701.	3.8	3,881
3	Calcium plus Vitamin D Supplementation and the Risk of Fractures. New England Journal of Medicine, 2006, 354, 669-683.	13.9	1,674
4	Long-Term Exposure to Air Pollution and Incidence of Cardiovascular Events in Women. New England Journal of Medicine, 2007, 356, 447-458.	13.9	1,538
5	The case for early detection. Nature Reviews Cancer, 2003, 3, 243-252.	12.8	1,014
6	Low-Fat Dietary Pattern and Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2006, 295, 655.	3.8	939
7	Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. New England Journal of Medicine, 2006, 354, 684-696.	13.9	907
8	Low-Fat Dietary Pattern and Risk of Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 629.	3.8	696
9	Implementation of the women's health initiative study design. Annals of Epidemiology, 2003, 13, S5-S17.	0.9	655
10	The women's health initiative recruitment methods and results. Annals of Epidemiology, 2003, 13, S18-S77.	0.9	653
11	Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. Journal of the National Cancer Institute, 2005, 97, 439-448.	3.0	539
12	Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA - Journal of the American Medical Association, 2006, 295, 1647.	3.8	497
13	Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures<SUBTITLE>The Women's Health Initiative Randomized Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2003, 290, 1739.	3.8	466
14	Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women. Journal of the National Cancer Institute, 2009, 101, 48-60.	3.0	465
15	Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women. JAMA - Journal of the American Medical Association, 2010, 304, 1684.	3.8	457
16	Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk. JAMA Oncology, 2015, 1, 611.	3.4	451
17	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	9.4	434
18	Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women. New England Journal of Medicine, 2009, 360, 573-587.	13.9	412

#	ARTICLE	IF	CITATIONS
19	Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA - Journal of the American Medical Association, 2017, 318, 927.	3.8	407
20	Low-Fat Dietary Pattern and Risk of Colorectal Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 643.	3.8	355
21	Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. JAMA - Journal of the American Medical Association, 2008, 299, 1036.	3.8	344
22	Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncology, The, 2012, 13, 476-486.	5.1	314
23	A cautionary note on inference for marginal regression models with longitudinal data and general correlated response data. Communications in Statistics Part B: Simulation and Computation, 1994, 23, 939-951.	0.6	288
24	Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women. Journal of the National Cancer Institute, 2007, 99, 1782-1792.	3.0	284
25	Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative) Tj ETQq1 1 0.784314 rgBT/Overlook 6.3 282	6.3	282
26	14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet, The, 2011, 378, 507-514.	6.3	239
27	Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas, 2006, 55, 103-115.	1.0	214
28	Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause. American Journal of Epidemiology, 2009, 170, 12-23.	1.6	211
29	Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA - Journal of the American Medical Association, 2020, 324, 369.	3.8	210
30	Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women. JAMA - Journal of the American Medical Association, 2011, 305, 267.	3.8	199
31	Low-Fat Dietary Pattern and Cancer Incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. Journal of the National Cancer Institute, 2007, 99, 1534-1543.	3.0	194
32	Insulin, Insulin-like Growth Factor-I, Endogenous Estradiol, and Risk of Colorectal Cancer in Postmenopausal Women. Cancer Research, 2008, 68, 329-337.	0.4	191
33	Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case-Control Study. Journal of the National Cancer Institute, 2010, 102, 26-38.	3.0	182
34	Selecting Differentially Expressed Genes from Microarray Experiments. Biometrics, 2003, 59, 133-142.	0.8	177
35	Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older. Journal of Clinical Oncology, 2011, 29, 2327-2333.	0.8	177
36	Multivitamin Use and Risk of Cancer and Cardiovascular Disease in the Women's Health Initiative Cohorts. Archives of Internal Medicine, 2009, 169, 294.	4.3	175

#	ARTICLE	IF	CITATIONS
37	Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 526-535.	3.0	165
38	Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms. <i>JAMA Internal Medicine</i> , 2014, 174, 1058.	2.6	160
39	Combined Analysis of Women's Health Initiative Observational and Clinical Trial Data on Postmenopausal Hormone Treatment and Cardiovascular Disease. <i>American Journal of Epidemiology</i> , 2006, 163, 589-599.	1.6	157
40	Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American Women. <i>Journal of the National Cancer Institute</i> , 2011, 103, 951-961.	3.0	148
41	Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers. <i>Clinical Cancer Research</i> , 2006, 12, 2117-2124.	3.2	136
42	Efficacy of exercise for menopausal symptoms. <i>Menopause</i> , 2014, 21, 330-338.	0.8	134
43	Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women. <i>American Journal of Epidemiology</i> , 2008, 167, 1207-1216.	1.6	126
44	Conjugated Equine Estrogens and Breast Cancer Risk in the Women's Health Initiative Clinical Trial and Observational Study. <i>American Journal of Epidemiology</i> , 2008, 167, 1407-1415.	1.6	126
45	Changing Concepts: Menopausal Hormone Therapy and Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 517-527.	3.0	125
46	Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1695-1705.	3.0	117
47	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724.	5.8	106
48	Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative. <i>Contemporary Clinical Trials</i> , 1996, 17, 509-525.	2.0	104
49	Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2919-2926.	0.8	104
50	Epidemiology of <i>Helicobacter pylori</i> infection in six Latin American countries (SWOG Trial S0701). <i>Cancer Causes and Control</i> , 2013, 24, 209-215.	0.8	102
51	Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1413-1421.	3.0	100
52	Efficacy of yoga for vasomotor symptoms. <i>Menopause</i> , 2014, 21, 339-346.	0.8	94
53	A Prospective Evaluation of Endogenous Sex Hormone Levels and Colorectal Cancer Risk in Postmenopausal Women. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv210.	3.0	92
54	Lessons Learned From the Women's Health Initiative Trials of Menopausal Hormone Therapy. <i>Obstetrics and Gynecology</i> , 2013, 121, 172-176.	1.2	89

#	ARTICLE	IF	CITATIONS
55	Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1419-1428.	0.8	87
56	The Women's Health Initiative: Lessons Learned. <i>Annual Review of Public Health</i> , 2008, 29, 131-150.	7.6	82
57	Obesity and the Risk for Premenopausal and Postmenopausal Breast Cancer. <i>Cancer Prevention Research</i> , 2012, 5, 515-521.	0.7	76
58	Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1081-1089.	1.1	76
59	Risk of Recurrent <i>Helicobacter pylori</i> Infection 1 Year After Initial Eradication Therapy in 7 Latin American Communities. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 578.	3.8	72
60	Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1490-1500.	2.2	71
61	Low-fat dietary pattern and cardiovascular disease: results from the Women's Health Initiative randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 35-43.	2.2	67
62	Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials. <i>Sleep</i> , 2018, 41, .	0.6	67
63	Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 244.e1-244.e11.	0.7	66
64	Weight loss and breast cancer incidence in postmenopausal women. <i>Cancer</i> , 2019, 125, 205-212.	2.0	66
65	Efficacy of omega-3 for vasomotor symptoms treatment. <i>Menopause</i> , 2014, 21, 347-354.	0.8	64
66	Correlates of maintenance of a low-fat diet among women in the Women's Health Trial. <i>Preventive Medicine</i> , 1992, 21, 279-291.	1.6	63
67	Statistical design and monitoring of the carotene and retinol efficacy trial (CARET). <i>Contemporary Clinical Trials</i> , 1993, 14, 308-324.	2.0	63
68	Heart Rate Variability, Ambient Particulate Matter Air Pollution, and Glucose Homeostasis: The Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative. <i>American Journal of Epidemiology</i> , 2009, 169, 693-703.	1.6	63
69	Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival. <i>JAMA Oncology</i> , 2018, 4, e181212.	3.4	62
70	Statistical Issues Arising in the Women's Health Initiative. <i>Biometrics</i> , 2005, 61, 899-911.	0.8	60
71	The influence of obesity-related factors in the etiology of renal cell carcinoma—A mendelian randomization study. <i>PLoS Medicine</i> , 2019, 16, e1002724.	3.9	59
72	Methods for the design of vasomotor symptom trials. <i>Menopause</i> , 2014, 21, 45-58.	0.8	57

#	ARTICLE	IF	CITATIONS
73	Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial. <i>Gynecologic Oncology</i> , 2010, 116, 323-325.	0.6	55
74	Use of alternative time scales in Cox proportional hazard models: implications for time-varying environmental exposures. <i>Statistics in Medicine</i> , 2012, 31, 3320-3327.	0.8	53
75	Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial. <i>Annals of Internal Medicine</i> , 2014, 160, 594.	2.0	53
76	Hormonal Factors and Risks of Esophageal Squamous Cell Carcinoma and Adenocarcinoma in Postmenopausal Women. <i>Cancer Prevention Research</i> , 2011, 4, 840-850.	0.7	50
77	Two-Stage Experimental Designs: Early Stopping with a Negative Result. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 1992, 41, 181.	0.5	47
78	Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1630-1634.	3.0	47
79	Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. <i>Obstetrics and Gynecology</i> , 2015, 126, 413-422.	1.2	47
80	Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 648-656.	1.1	47
81	Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. <i>Journal of the National Cancer Institute</i> , 2019, 111, 137-145.	3.0	43
82	Effects of Blood Collection Conditions on Ovarian Cancer Serum Markers. <i>PLoS ONE</i> , 2007, 2, e1281.	1.1	42
83	The Women's Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study: Description and Baseline Characteristics of Participants. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 125-137.	1.1	42
84	Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 49.	3.8	41
85	Effects on response rates and costs of stamps vs business reply in a mail survey of physicians. <i>Journal of Clinical Epidemiology</i> , 1993, 46, 455-459.	2.4	39
86	Low-Fat Dietary Pattern among Postmenopausal Women Influences Long-Term Cancer, Cardiovascular Disease, and Diabetes Outcomes. <i>Journal of Nutrition</i> , 2019, 149, 1565-1574.	1.3	39
87	The Role of Antioxidants and Vitamin A in Ovarian Cancer: Results From the Women's Health Initiative. <i>Nutrition and Cancer</i> , 2008, 60, 710-719.	0.9	36
88	Ambient Fine Particulate Matter Exposure and Myocardial Ischemia in the Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative (EEAWHI) Study. <i>Environmental Health Perspectives</i> , 2009, 117, 751-756.	2.8	36
89	Inflammation and Oxidative Stress Markers and Esophageal Adenocarcinoma Incidence in a Barrett's Esophagus Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2393-2403.	1.1	35
90	Effects of Yoga and Aerobic Exercise on Actigraphic Sleep Parameters in Menopausal Women with Hot Flashes. <i>Journal of Clinical Sleep Medicine</i> , 2017, 13, 11-18.	1.4	35

#	ARTICLE	IF	CITATIONS
91	Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity. <i>Steroids</i> , 2014, 90, 53-59.	0.8	32
92	Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. <i>Cancer Causes and Control</i> , 2014, 25, 969-976.	0.8	31
93	Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz029.	1.4	30
94	Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index: Figure 1.. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv327.	3.0	29
95	Application of blood concentration biomarkers in nutritional epidemiology: example of carotenoid and tocopherol intake in relation to chronic disease risk. <i>American Journal of Clinical Nutrition</i> , 2019, 109, 1189-1196.	2.2	27
96	Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age. <i>American Journal of Epidemiology</i> , 2021, 190, 365-375.	1.6	27
97	Coronary Heart Disease and Stroke with Aromatase Inhibitor, Tamoxifen, and Menopausal Hormone Therapy Use. <i>Clinical Breast Cancer</i> , 2006, 6, S58-S64.	1.1	26
98	Menopausal hormone therapy and breast cancer mortality: clinical implications. <i>Therapeutic Advances in Drug Safety</i> , 2015, 6, 45-56.	1.0	26
99	Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1059-1063.	1.1	25
100	Association of Prediagnostic Frailty, Change in Frailty Status, and Mortality After Cancer Diagnosis in the Women's Health Initiative. <i>JAMA Network Open</i> , 2020, 3, e2016747.	2.8	25
101	Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. <i>Clinical Trials</i> , 2007, 4, 207-217.	0.7	23
102	Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 969-979.	1.1	23
103	Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. <i>Breast Cancer Research</i> , 2014, 16, R30.	2.2	22
104	Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study. <i>Breast Cancer Research</i> , 2017, 19, 28.	2.2	21
105	Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	20
106	Use of administrative data to increase the practicality of clinical trials: Insights from the Women's Health Initiative. <i>Clinical Trials</i> , 2016, 13, 519-526.	0.7	19
107	The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative. <i>European Journal of Heart Failure</i> , 2021, 23, 1712-1721.	2.9	19
108	Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett's esophagus. <i>BMC Obesity</i> , 2015, 2, 32.	3.1	18

#	ARTICLE	IF	CITATIONS
109	Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1186-1190.	0.8	17
110	Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 139, 253-260.	0.6	17
111	Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. <i>Cancer</i> , 2020, 126, 2956-2964.	2.0	17
112	Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1501-1510.	2.2	17
113	Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 917-924.	2.3	16
114	Optimal Cutoffs of Obesity Measures in Relation to Cancer Risk in Postmenopausal Women in the Women's Health Initiative Study. <i>Journal of Women's Health</i> , 2015, 24, 218-227.	1.5	16
115	Lights on MsFLASH: a review of contributions. <i>Menopause</i> , 2020, 27, 473-484.	0.8	16
116	The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 747-757.	1.1	16
117	The Influence of Time From Menopause and Mammography on Hormone Therapy-Related Breast Cancer Risk Assessment. <i>Journal of the National Cancer Institute</i> , 2011, 103, 284-285.	3.0	15
118	Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. <i>International Journal of Cancer</i> , 2019, 145, 2051-2060.	2.3	15
119	Prediagnosis social support, social integration, living status, and colorectal cancer mortality in postmenopausal women from the women's health initiative. <i>Cancer</i> , 2020, 126, 1766-1775.	2.0	15
120	Individually randomized intervention trials for disease prevention and control. <i>Statistical Methods in Medical Research</i> , 1999, 8, 287-309.	0.7	14
121	Sitting, physical activity, and serum oestrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study. <i>British Journal of Cancer</i> , 2017, 117, 1070-1078.	2.9	14
122	Low-Fat Dietary Pattern and Cancer Mortality in the Women's Health Initiative (WHI) Randomized Controlled Trial. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky065.	1.4	14
123	Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). <i>Cancer Prevention Research</i> , 2019, 12, 481-490.	0.7	14
124	Nutritional epidemiology and the Women's Health Initiative: a review. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1083-1092.	2.2	14
125	Incidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET). <i>Genome Medicine</i> , 2013, 5, 7.	3.6	13
126	Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study. <i>Cancer Causes and Control</i> , 2019, 30, 1201-1211.	0.8	13

#	ARTICLE	IF	CITATIONS
127	Southwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 114, 206-209.	0.6	11
128	The Impact of the COVID-19 Pandemic on Older Women in the Women's Health Initiative. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, S3-S12.	1.7	11
129	The Yet Unrealized Promise of Ovarian Cancer Screening. <i>JAMA Oncology</i> , 2018, 4, 456.	3.4	10
130	Design and baseline characteristics of participants in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS). <i>Contemporary Clinical Trials</i> , 2022, 116, 106728.	0.8	10
131	Ovarian Cancer Biomarker Screening: Still Too Early to Tell. <i>Women's Health</i> , 2010, 6, 487-490.	0.7	9
132	Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study. <i>International Journal of Cancer</i> , 2020, 147, 404-412.	2.3	9
133	Estimation of the Correlation Between Nutrient Intake Measures Under Restricted Sampling. <i>Biometrics</i> , 1999, 55, 711-717.	0.8	8
134	Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?. <i>International Journal of Cancer</i> , 2019, 144, 730-740.	2.3	8
135	Can dietary self-reports usefully complement blood concentrations for estimation of micronutrient intake and chronic disease associations?. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 168-179.	2.2	8
136	Determinants, circumstances and consequences of injurious falls among older women living in the community. <i>Injury Prevention</i> , 2021, 27, 34-41.	1.2	8
137	Obesity, Height, and Serum Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2018-2029.	1.1	8
138	Migraine History, Nonsteroidal Anti-inflammatory Drug Use, and Risk of Postmenopausal Endometrial Cancer. <i>Hormones and Cancer</i> , 2012, 3, 240-248.	4.9	7
139	Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. <i>American Journal of Epidemiology</i> , 2020, 189, 972-981.	1.6	7
140	Model Misspecification in Proportional Hazards Regression. <i>Biometrika</i> , 1995, 82, 527.	1.3	6
141	Contributions of the Women's Health Initiative to Cardiovascular Research. <i>Journal of the American College of Cardiology</i> , 2022, 80, 256-275.	1.2	5
142	Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. <i>Cancer Epidemiology</i> , 2018, 56, 83-89.	0.8	4
143	Mediation by differential DNA methylation of known associations between single nucleotide polymorphisms and bladder cancer risk. <i>BMC Medical Genetics</i> , 2020, 21, 228.	2.1	4
144	AIR POLLUTION AND CARDIOVASCULAR DISEASE EVENTS IN THE WOMEN'S HEALTH INITIATIVE OBSERVATIONAL (WHI-OS) STUDY. <i>Epidemiology</i> , 2004, 15, S28-S29.	1.2	3

#	ARTICLE	IF	CITATIONS
145	Treatment of <i>Helicobacter pylori</i> in Latin America – Authors' reply. <i>Lancet, The</i> , 2012, 379, 408-409.	6.3	3
146	An Environmental Scan of Biopsychosocial and Clinical Variables in Cohort Studies of Cancer Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1621-1641.	1.1	3
147	Su1673 <i>H. pylori</i> Recurrence One Year After Eradication Treatment in a Population Randomized Trial (SWOG S0701) in Seven Latin American Sites. <i>Gastroenterology</i> , 2012, 142, S-478-S-479.	0.6	2
148	1046 Predictors of Success of <i>Helicobacter pylori</i> Eradication Treatment in a Multicentric Randomized Clinical Trial (SWOG S0701) in Latin America. <i>Gastroenterology</i> , 2012, 142, S-183-S-184.	0.6	2
149	The Association of Predicted Resting Energy Expenditure with Risk of Breast Cancer among Postmenopausal Women in the Women's Health Initiative Cohort. <i>Cancer Prevention Research</i> , 2022, 15, 255-264.	0.7	2
150	Concerns about published data from the estrogen-progestin (HT) arm of the WHI. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 192, 333.	0.7	1
151	Low-Fat Diet and Cardiovascular Disease – Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 279.	3.8	1
152	Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. <i>Obstetrical and Gynecological Survey</i> , 2008, 63, 440-442.	0.2	1
153	Lung cancer and hormone replacement therapy – Authors' reply. <i>Lancet, The</i> , 2010, 375, 118-119.	6.3	1
154	Su1677 Risk Factors for <i>Helicobacter pylori</i> Infection in Six Latin American Countries (SWOG Trial) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.6	1
155	A Statistical Perspective on Prevention Trials: A View from the Women's Health Initiative. <i>Statistics in Biosciences</i> , 2013, 5, 330-343.	0.6	1
156	Women's Health Initiative View of Estrogen Avoidance and All-Cause Mortality. <i>American Journal of Public Health</i> , 2013, 103, e2-e2.	1.5	1
157	Narrowing of racial disparities in breast cancer incidence: insights from menopausal hormone therapy study findings. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv393.	3.0	1
158	Reply to The Women's Health Initiative; hormone replacement therapy; and Surveillance, Epidemiology, and End Results data and The importance of comprehensive data and statistical testing in the interpretation of breast cancer incidence trends. <i>Cancer</i> , 2021, 127, 813-814.	2.0	1
159	Mortality Associated with Healthy Eating Index Components and an Empirical-scores Healthy Eating Index in a Cohort of Postmenopausal Women. <i>Journal of Nutrition</i> , 2022, , .	1.3	1
160	Constitutional <i>BRCA1</i> methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10509-10509.	0.8	1
161	Breast Cancer in Postmenopausal Women After Hormone Therapy – Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 466.	3.8	0
162	Association Between Obesity and Postmenopausal Breast Cancer Risk – Reply. <i>JAMA Oncology</i> , 2015, 1, 1171.	3.4	0

#	ARTICLE	IF	CITATIONS
163	Recreational physical activity, sitting, and androgen metabolism among postmenopausal women in the Women's Health Initiative Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0809.2021.	1.1	0
164	Lifestyle Factors and Risk of Breast Cancer: A Review of Randomized Trial Findings. , 2010, , 23-41.		0
165	Abstract 1031: Estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy. , 2012, , .		0
166	Analgesic Use and Circulating Estrogens, Androgens, and Their Metabolites in the Women's Health Initiative Observational Study. Cancer Prevention Research, 2022, 15, 173-183.	0.7	0